Related Experiment Videos
Circulating tumour markers in ovarian tumours
1Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, UK.
Forum (Genoa, Italy)
|September 6, 2001
Summary
Cancer antigen-125 (CA-125) is the primary biomarker for diagnosing, monitoring, and detecting relapse in epithelial ovarian cancer (OC). Its role in prognosis, follow-up, and screening requires further definition.
Area of Science:
- Gynecologic Oncology
- Clinical Chemistry
- Biomarker Discovery
Background:
- Ovarian tumors are managed using various circulating tumor markers.
- Cancer antigen-125 (CA-125) is the sole established marker for epithelial ovarian cancer (OC) diagnosis, treatment monitoring, and relapse detection.
- The utility of markers for OC prognosis, follow-up, and screening is not well-established.
Purpose of the Study:
- To review the role of CA-125 in epithelial ovarian cancer management.
- To discuss other markers used in epithelial OC.
- To explore markers for other ovarian tumor types, including germ cell, mixed Mullerian, and stromal tumors.
Main Methods:
- Literature review focusing on ovarian cancer biomarkers.
- Analysis of the established and potential roles of CA-125.
- Discussion of additional markers relevant to various ovarian tumor histologies.
Main Results:
- CA-125 is the principal biomarker with a defined role in epithelial OC.
- The prognostic and screening utility of CA-125 requires further investigation.
- Various other markers are utilized or under investigation for different ovarian tumor types.
Conclusions:
- CA-125 is crucial for epithelial ovarian cancer diagnosis, treatment monitoring, and relapse detection.
- Further research is needed to clarify the role of CA-125 in predicting prognosis, follow-up, and screening for OC.
- A range of markers are relevant for managing diverse ovarian tumor types beyond epithelial OC.